End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.37 USD | -1.69% | -7.15% | +16.46% |
Apr. 30 | Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals | MT |
Apr. 30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
Financials (USD)
Sales 2024 * | 353M | Sales 2025 * | 606M | Capitalization | 3.74B |
---|---|---|---|---|---|
Net income 2024 * | -149M | Net income 2025 * | 30M | EV / Sales 2024 * | 14.7 x |
Net Debt 2024 * | 1.46B | Net Debt 2025 * | 1.28B | EV / Sales 2025 * | 8.27 x |
P/E ratio 2024 * |
-22.4
x | P/E ratio 2025 * |
129
x | Employees | 999 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.2% |
Latest transcript on Alvotech
1 day | -1.69% | ||
1 week | -7.15% | ||
Current month | -7.79% | ||
1 month | +12.83% | ||
3 months | -14.62% | ||
6 months | +48.39% | ||
Current year | +16.46% |
Managers | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 12-12-31 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 20-01-31 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 69 | 22-06-15 |
Helga Zharov
LAW | General Counsel | 57 | 20-04-30 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 13.37 | -1.69% | 55,205 |
24-05-09 | 13.6 | +0.44% | 41,632 |
24-05-08 | 13.54 | -2.31% | 66,819 |
24-05-07 | 13.86 | -3.62% | 166,408 |
24-05-06 | 14.38 | -0.14% | 134,650 |
End-of-day quote Nasdaq, May 09, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.46% | 3.74B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ALVO Stock